Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanguang Hu

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Cancer Biology & Therapy|October 12, 2018
Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencingMengyuan Yang, Xuefeng Fang, Jun Li, et al.
Epigenomics|August 26, 2021
SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylationHanguang Hu, Dehao Wu, Xibo Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2012
Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancersHanguang Hu, Hang Zhang, Weiting Ge, et al.
BMC Cancer|July 18, 2023
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric studyXuefeng Fang, Chenhan Zhong, Shanshan Weng, et al.
Plos One|January 10, 2013
Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesisDonger Zhou, Liu Yang, Liangtao Zheng, et al.
International Journal of Cancer|November 7, 2019
High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironmentWeiting Ge, Hanguang Hu, Wen Cai, et al.
BMC Medicine|May 5, 2022
Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyYue Liu, Qian Xiao, Jinjie He, et al.
Clinical and Translational Medicine|September 8, 2020
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Qing Wei, Xiaoying Wu, et al.
Eclinicalmedicine|August 9, 2023
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialXuefeng Fang, Ning Zhu, Chenhan Zhong, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancer Biology & Therapy|October 12, 2018
Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencingMengyuan Yang, Xuefeng Fang, Jun Li, et al.
Epigenomics|August 26, 2021
SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylationHanguang Hu, Dehao Wu, Xibo Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2012
Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancersHanguang Hu, Hang Zhang, Weiting Ge, et al.
BMC Cancer|July 18, 2023
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric studyXuefeng Fang, Chenhan Zhong, Shanshan Weng, et al.
Plos One|January 10, 2013
Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesisDonger Zhou, Liu Yang, Liangtao Zheng, et al.
International Journal of Cancer|November 7, 2019
High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironmentWeiting Ge, Hanguang Hu, Wen Cai, et al.
BMC Medicine|May 5, 2022
Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyYue Liu, Qian Xiao, Jinjie He, et al.
Clinical and Translational Medicine|September 8, 2020
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Qing Wei, Xiaoying Wu, et al.
Eclinicalmedicine|August 9, 2023
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialXuefeng Fang, Ning Zhu, Chenhan Zhong, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
Pageof 4